Clinical Trials
14 trialsNCT04889716 2026-05-26
CAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT07443137 2026-05-08
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Phase 1 Not yet recruiting
NCT06014762 2026-05-07
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT07570823 2026-05-06
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sinocelltech Ltd.
Phase 3 Not yet recruiting
NCT07249905 2026-05-04
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT02315612 2026-04-28
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07552324 2026-04-27
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07548697 2026-04-23
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT05020678 2026-04-20
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Phase 1 Active not recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT07511114 2026-04-06
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Ruijin Hospital
Phase 3 Not yet recruiting
NCT06481826 2026-03-27
Glofitamab in Chinese Patients With R/R DLBCL
Peking Union Medical College Hospital
Recruiting
NCT07472621 2026-03-16
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Henan Cancer Hospital
Not yet recruiting